PUBLIC COMPANY
save$TPSTTempest Therapeutics, Inc.
$TPSTBrisbane, CA, USupdated 3mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Preclinical1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
- phase3A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
- phase1TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
🐶 Hiring Signal
News
- 9 biotechs will cut at least half their California workforcesWorkforce reductions have hit over 1,000 biopharma employees in The Golden State year to date, with pink slips coming from small biotechs and large pharmas. Biotechs have been hit the hardest, with…biospace · 1d ago
- An eye drug biotech banks $118M and stocks its executive suiteClaris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.biopharma_dive · 3mo ago
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that